108
EXHIBIT 31.2
------------
This is an Exhibit to the Form 20-F of Sinovac Biotech Ltd.
-----------------------------------------------------------
Attached find the following materials:
Certification of Disclosure in Sinovac Biotech Ltd.'s Annual Report
-------------------------------------------------------------------
by Lily Wang
------------
109
Certification of Disclosure in
Sinovac Biotech Ltd.'s Annual Report
------------------------------------
I, Lily Wang, certify that:
1. I have reviewed and read this annual report on Form 20-F/A-3 of Sinovac
Biotech Ltd.;
2. Based on my knowledge, this report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of
the company as of, and for, the periods presented in this report;
4. The company's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:
(a) designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
company, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in
which this report is being prepared;
(b) evaluated the effectiveness of the company's disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and
(c) disclosed in this report any change in the company's internal control
over financial reporting that occurred during the period covered y the
annual report that has materially affected, or is reasonable likely to
materially affect, the company's internal control over financial
reporting; and
5. The company's other certifying officer and I have disclosed, based on our
most recent evaluations of internal control over financial reporting, to
the company's auditors and the audit committee of the company's board of
directors (or persons performing the equivalent functions):
(a) all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
110
reasonably likely to adversely affect the company's ability to record,
process, summarize and report financial information; and
(b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the company's internal
control over financial reporting.
Dated: November 21, 2005 /s/ Lily Wang
-----------------------------------
Lily Wang, Chief Financial Officer
and Director (Principal Accounting
Officer)
End of Exhibit 31.2
----------